This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Proteasome (prosome macropain) 26S subunit non-ATPase 10 (PSMD10; gankyrin)	<i>In vitro</i> , mouse and patient sample studies suggest that inhibiting gankyrin could help treat K-Ras (KRAS) mutant cancers. In human lung adenocarcinomas with K-Ras mutations, gankyrin expression was higher than that in normal tissues and lung cancers without K-Ras mutations. In mouse embryonic fibroblasts with constitutively activated Ras and increased gankyrin levels, small interfering RNA-mediated gankyrin knockout decreased pro-oncogenic protein kinase B (PKB; Akt) phosphorylation compared with that seen using scrambled siRNA controls. In mice injected with embryonic fibroblasts, anti-gankyrin siRNA led to absence of tumors compared with scrambled control siRNA. Next steps could include identifying pharmacological inhibitors of gankyrin.	Patent and licensing status unavailable	Man, J.-H. <i>et al. J. Clin. Invest.</i> ; published online July 12, 2010; doi:10.1172/JCI42542 Contact: Xue-Min Zhang, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, China e-mail: xmzhang@nic.bmi.ac.cn Contact: Hui-Yan Li, same affiliation as above e-mail: lhy@proteomics.cn
<i>SciBX</i> 3(29); doi:10.1038/scibx.2010.889 Published online July 29, 2010				